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Abstract:  Human  immunodeficiency  virus  (HIV)  infection  is  principally  a  mucosal 
disease and the gastrointestinal (GI) tract is the major site of HIV replication. Loss of 
CD4
+ T cells and systemic immune hyperactivation are the hallmarks of HIV infection. 
The end of acute infection is associated with the emergence of specific CD4+ and CD8+ T 
cell responses and the establishment of a chronic phase of infection. Abnormal levels of 
immune activation and inflammation persist despite a low steady state level of viremia. 
Although  the  causes  of  persistent  immune  hyperactivation  remain  incompletely 
characterized, physiological alterations of gastrointestinal tract probably play a major role. 
Failure to restore Th17 cells in gut-associated lymphoid tissues (GALT) might impair the 
recovery  of  the  gut  mucosal  barrier.  This  review  discusses  recent  advances  on 
understanding the contribution of CD4
+ T cell depletion to HIV pathogenesis. 
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1. Introduction 
Programmed cell death (PCD) and necrosis are two major processes by which cells die. Necrosis 
normally results from a severe cellular insult, which may lead to macrophage activation and the release 
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of proinflammatory cytokines. These cytokines act as a ―danger signal‖ and provide the costimulation 
required  for  T  cell  activation  and  immunity.  Apoptosis,  type  I  PCD,  is  a  fundamental  biological 
process  in  development  and  cellular  homeostasis  and  occurs  without  inflammation  or  injury  to 
surrounding tissues. Apoptosis is involved in embryonic development, hormonal regulation, immunity, 
regulation  of  inflammation  and  neoplasia.  It  is  a  controlled  process,  in  organogenesis  and  tissue 
remodeling  during  development,  to  eliminate  used-up,  damaged,  or  misplaced  cells  during  the 
embryonic  development  and  the  tissue  homeostasis  of  multicellular  organisms.  Deregulation  of 
apoptosis  can  disrupt  the  balance  between  proliferation  and  cell  death.  Failure  of  cells  to  die  is  
an  integral  mechanism  leading  to  malignancies  such  as  cancer,  and  autoimmune  phenomena. 
Conversely,  an  abnormal  increase  in  cell  death  is  observed  in  neurodegenerative  disorders  or  in  
immunodeficiency [1]. So, in order to preserve homeostasis in a given system, it is crucial to maintain 
an equilibrium in the expression control among genes that promote proliferation, genes that influence 
survival/death and genes that inhibit proliferation. 
There are a wide variety of stimuli and conditions, both physiological and pathological, which can 
trigger apoptosis. It is an energy-dependent process which implicates the activation of a group of 
cysteine proteases called caspases in a complex cascade of events. Depending on the initiating stimuli, 
two major mechanisms could be defined: the intrinsic pathway or mitochondrial pathway [2], that 
involves members of the bcl-2 family and mitochondrial functions, such as the role of mitochondrial 
membrane potential (m) in which fluctuations appear to be central to the distribution of proapoptotic 
molecules; and the extrinsic pathway which is activated by extracellular signals that act via death 
receptors (DR) [3,4] (Figure 1). Several DRs have been described that all belong to the tumor necrosis 
factor (TNF) receptor superfamily. Each pathway activates its own initiator caspase which, in turn, 
will activate the executioner caspase-3. There are evidences that the two pathways are linked and that 
molecules in one pathway can influence the other [5]. A third pathway, involving T-cell mediated 
cytotoxicity and perforin/granzyme dependent killing of cell works in a caspase-independent fashion 
(Figure 1). Autophagy, type II PCD, is a highly regulated physiological mechanism conserved among 
the evolution from yeast to mammals. Autophagy, a cellular catabolic pathway, is a process by which 
the cell, using membranes to isolate organelles or regions of cytoplasm, eliminates damaged organelles 
or consumes intracellular components as resources during starvation or other limiting condition [6]. It 
is a complex process as it can lead to cell survival as cell death. Apoptosis and autophagy are not 
mutually exclusive and the molecular regulators of both pathways are inter-connected leading to a 
cross-talk  [7].  Autophagy  is  also  a  mechanism  involved  in  innate  and  adaptive  immunity  against 
pathogens, and is a fundamental antiviral mechanism [8]. 
A fundamental characteristic of the immune system is its ability to expand rapidly the number of 
antigen-specific lymphocytes to combat pathogens. Apoptosis is of crucial importance for termination 
of the acquired immune response. This immune response is a multistep process: naïve T cells are 
activated through cross-linking of antigen to the T-cell receptor (TCR), leading to proliferation and 
differentiation  into  effector  cells.  After  expansion  of  antigen-specific  T  cells,  the  majority  of  the 
activated T cells enter the so-called deletion phase and are eliminated to prevent undesirable immune 
responses  such  as  autoimmunity  whereas  a  portion  of  them  survive  as  memory  T  cells  [9].  The 
apoptotic  process  of  elimination  of  activated  T  cells  during  the  termination  phase  of  an  immune 
response is called activation-induced cell death (AICD) [10–12]. Viruses 2011, 3                         
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Figure 1. The extrinsic (death receptor-mediated) and intrinsic (mitochondria-mediated) 
pathways that lead to apoptosis of HIV infected helper T cells. The main HIV proteins (in 
red) implicated in CD4
+ T cell death are the envelope glycoprotein gp120, the negative 
effector Nef, the transactivator of transcription (TAT) and the viral protein R (vpr). HIV 
gp120  uses  CD4  on  helper  T  cells  and  the  chemokine  receptors  CCR5  or  CXCR4  as 
coreceptors for virus cell entry and upregulates Fas-ligand (FASL) on these cells. Soluble 
Nef protein interacts directly with CXCR4 to induce cell apoptosis. Exogenous Nef protein 
directly stimulates TCR-CD3 complex and upregulates Fas/FasL expression on the cell 
surface  while  inhibiting  the  anti-apoptotic  proteins  Bcl-2  family.  As  endogenous  Nef 
protein, Tat upregulates the Fas/FasL pathway and directly activates caspase 8. Tat and 
Vpr inhibit bcl-2 family while increasing mitochondria dysfunctions and cytochrome c 
release that promotes the formation of the apoptosome. HIV-1 Vpr also arrests cells in the 
G2  phase  of  the  cell  cycle.  TCR:  T  cell  receptor;  CTL:  cytotoxic  T  lymphocyte;  
FasL:  Fas  ligand;  FADD:  Fas-associated  death  domain;  Caspase:  cysteinyl  aspartic  
acid-protease; BCL-2: B-cell lymphoma  protein 2;  BCL-X: BCL-2 like 1; Bax:  BCL2 
associated X protein; APAF: Apoptotic protease activating factor; PTPC : permeability 
transition pore complex. 
Figure 1 Fevrier et al., 2010
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Pathogens have evolved molecules that affect the death pathway [13]. Human immunodeficiency 
virus  (HIV)  type-1  appears  to  induce  cell  death  whereas  other  pathogens  preserve  their  host  by 
inhibiting the induction of a cell death pathway. This review presents an overview of the relationship 
between HIV-1 and CD4
+ T cell death that complements the information presented in a recent review 
by Cummins and Bradley [14]. Literature concerning nonhuman primates naturally or experimentally 
infected  with  SIV  (Simian  Immunodeficiency  Virus)  is  as  important  as  literature  concerning  
HIV-infected humans. This is the reason why we have decided to focus, in this review, only on recent 
data concerning humans infected with HIV-1, to try to understand how HIV is able to destroy CD4
+ T 
cells which take a central position in the immune system. 
2. HIV: Structure and Pathology 
2.1. The Virus 
HIV-1, the causative agent of AIDS (Acquired ImmunoDeficiency Syndrome) in human, belongs to 
the  Lentivirus  genus  of  the  Retroviridae  family.  This  family  has  a  unique  enzyme  called  reverse 
transcriptase that converts viral RNA to DNA upon viral entry into the cell. The genome of HIV, 
composed  of  two  identical  copies  of  single  stranded  RNA  molecules,  encodes  nine  open  reading 
frames that produce 15 proteins, defining two general classes of proteins, structural and regulatory [15]. 
The three structural proteins are Gag, Pol and Env polyproteins which are subsequently proteolyzed 
into individual proteins: (1) the four Gag proteins, MA (matrix), CA (capsid), NC (nucleocapsid) and 
p6, (2) the two Env proteins, SU (surface or gp120) and TM (transmembrane or gp41) are structural 
components that make up the core of the virion and outer membrane envelope; and (3) the three Pol 
proteins, PR (protease), RT (reverse transcriptase) and IN (integrase), provide essential enzymatic 
functions and are also encapsulated within the particle. HIV encodes six additional proteins: Tat and 
Rev provide essential gene regulatory functions and four additional proteins often called accessory 
proteins, Vif, Vpr and Nef are found in the viral particle, whereas Vpu indirectly assists in assembly of 
the virion [16]. 
Cell entry of HIV is mediated by the binding of the viral envelope glycoprotein (Env) to the CD4 
molecule  on  target  cells  along  with  a  chemokine  coreceptor,  such  as  CCR5  or  CXCR4  [17] 
determining  the  tropism  of  the  virus  (R5  or  X4  respectively)  for  particular  cell  types  (Figure  1). 
However, the majority of newly transmitted HIV strains uses CCR5 as a coreceptor [18]. CD4
+ T cells, 
macrophages, monocytes and microglial cells are infected and killed by the virus [19,20], but activated 
CD4
+ T cells are the optimal viral targets since HIV more efficiently infects and replicates in these 
cells  [21].  After  binding  of  the  virus  and  entry,  viral  RNA  is  retro-transcribed  and  the  provirus 
integrated  into  the  cellular  genome;  virus  proteins  are  then  synthesized,  the  virus  assembled  and 
budding occurs. 
2.2. Pathology 
HIV  is  transmitted  primarily  through  blood  and  genital  fluids  and  to  newborn  infants  from 
infected mothers. Viruses 2011, 3                         
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HIV infection is principally a mucosal disease and events occurring in blood may not reflect events 
occurring at mucosal surfaces. The gastrointestinal (GI) tract is the major site of HIV replication, 
which results in massive depletion of lamina propria CD4
+ T cells [22,23], in the first 3–6 weeks of 
infection and is maintained throughout the chronic phase. Years of antiretroviral therapy allow only a 
partial restoration of these CD4
+ T cell populations. T cells in the blood or lymph nodes do not show 
the same degree of depletion: in acute HIV infection, blood CD4
+ T cell numbers decline sharply, but 
as  soon  as  antiviral  immune  response  is  established,  these  cells  have  the  potential  to  reach  a 
moderately subnormal level [24]. Following the initial peak of viremia, HIV-specific humoral and  
cell-mediated immune responses are readily detected; in particular HIV-specific CTL play a major role 
in the initial downregulation of virus replication in peripheral blood [25]. These immune responses 
generated by the host partly control viral replication, viremia declines by several orders of magnitude 
until it reaches a lower steady state level (viral setpoint); but these responses fail to eliminate the virus 
leading to a chronic infection in most individuals during an asymptomatic period which can go on 
several years. During the chronic phase of the infection, blood CD4
+ T cell count declines slowly; this 
loss can be partially reversed by successful antiretroviral treatment, but it is accelerated during AIDS. 
Studies of large cohorts of HIV-infected individuals have clearly indicated that the rate of progression 
of HIV disease may be substantially different. Among the total population of HIV-infected individuals, 
the majority (70%–80%) belong to the group of typical progressors (the median time from initial 
infection to progression to AIDS is five to ten years). However, four additional subgroups have been 
identified  [26]:  rapid  progressors  who  have  an  unusually  rapid  disease  progression  (AIDS  or  
AIDS-related death within three years after seroconversion); the long-term nonprogressors (LTNP, 
two subgroups)  [27]  without  progressive  disease  for  several  years  (eight  to  ten)  and  the  elite 
controllers with a viral load well below the detection limit of most conventional tests [28]. 
The viral persistence during the chronic phase of the infection is due in part to latent HIV reservoirs 
in  resting  CD4
+  T  cells  [29]  and  additional  cell  populations  [30,31].  HIV-1  infection  causes  a 
generalized state of immune dysfunction characterized by simultaneous chronic immune activation 
[32] associated with a paradoxical anergy in both CD4
+ and CD8
+ T cell compartments resulting in 
increased susceptibility to opportunistic infections and malignancy [33,34]. Proliferation of memory T 
cells is markedly elevated but the average lifespans of these cells are dramatically shortened [24,35]. 
3. Cellular Immunology of HIV 
3.1. CD4
+ T Cell Subpopulations 
CD4
+ T cells orchestrate immune responses by differentiating into T helper (Th) cell subsets which 
recruit  and  activate  other  immune  cells  including  B  cells,  CD8
+  T  cells,  macrophages  and  other 
effector  cells.  The  diverse  functions  of  CD4
+  T  cells  are  determined  by  their  cytokine  secretion 
patterns and their tissue locations (Figure 2). In 1986, Mosmann et al. [36] divided T cell clones into 
two subsets, Th1 and Th2, which respectively produced the signature cytokines interferon (IFN) and 
interleukin (IL)-4 and IL-13. Th1 cells promote the cytotoxic effector functions of natural killer (NK) 
cells, CD8
+ T cells and macrophages and are important for clearance of intracellular pathogens as 
viruses,  intracellular  bacteria  and  protozoan  parasites.  They  also  promote  antibody-dependent  Viruses 2011, 3                         
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cell-mediated cytotoxicity (ADCC) by supporting B cell production of IgG1 in humans. By contrast, 
Th2 cells promote humoral immunity, mediated by B cell-produced IgG4 and IgE in humans and are 
critical  for  clearance  of  extracellular  parasites.  The  appropriate  development  of  polarized  Th  cell 
responses to different classes of pathogens is still under investigation [37]. 
Most of CD4
+ T cells reside within the gastrointestinal (GI) tract, lymph nodes (LNs) and other 
lymphatic tissues rather than in peripheral blood [38,39]. In the GI tract, the majority of CD4
+ T cells 
are  CCR5
+  memory  cells  and  constitute  ideal  viral  targets  [40,41].  Indeed  these  cells  are  very 
permissive to in vitro HIV infections [42]. 
Recently, this dualistic view of Th cell lineages has been complicated by the recognition of two new 
major  subsets  of  Th  cells,  namely  Th17  and  Treg  cells  although  others  lineages  may  exist  [43] 
(Figure 2). 
Figure 2. Differentiation of effector CD4
+ T cells. Following activation by a given antigen, 
cytokines secreted in the microenvironment dictate the type of effector cells subsequently 
induced from naive T cells. Th1, Th2, Th9, Th17, TH22, TFH and Treg lineages are defined 
depending on the expression of transcription factors, effector cytokines, and chemokine 
receptors. Fully functional Th cells contribute to the immune response. 
Figure 2 Fevrier et al., 2010
 
 
Th17 cells, a subset of helper T cells, are identified in situ as a population of CD4
+ memory T cells 
expressing  the  IL-23  receptor  (IL-23R),  CCR6  and  the  transcription  factor  ROR-t.  In  peripheral Viruses 2011, 3                         
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blood,  approximately  0.4%  of  CD4
+  T  cells  are  IL17
+CD4
+  T  cells.  Most  of  them  are 
CD45RA
−CD45RO
+  [44].  They  are  important  for  intestinal  homeostasis  and  are  characterized  by 
secretion of the proinflammatory cytokines IL-17, IL-1, IL-6, IL21, IL-22 and TNF-. These cells 
arise exclusively from a population of CD161
+CD4
+ T cells in the presence of IL-1 and IL-23, and 
this precursor population has gut-homing potential (for review see [45]). They mediate inflammation 
and development of autoimmune diseases [46] but they also confer protection against extracellular 
bacteria,  fungi  and  mycobacteria  [47].  Th17  are  involved  in  control  of  epithelial  integrity  of  the 
gastrointestinal barrier and microbial invasion. 
Regulatory T (Tregs) cells are a subset of circulating CD4
+ T cells with suppressive properties 
implicated in the control of self immune tolerance [48], auto-immune diseases, cancer, transplantation, 
materno-fetal  tolerance  and  inflammation  induced  by  chronic  pathogens  [49,50].  They  are 
phenotypically defined as CD4
+CD25
+FoxP3
+; their development, maintenance and function require 
the expression of the master transcription factor FoxP3 (forkhead box P3) [51,52]. They express also 
the memory marker CD45RO and several activation markers such as HLA-DR [53,54]. Natural Tregs 
(nTreg)  are  generated  in  the  thymus  [55],  would  prevent  autoimmunity  and  raise  the  activation 
threshold for all immune responses [56]. Adaptive or induced Tregs (iTregs) develop in the periphery 
from mainstream peripheral T cells using self [57] or foreign antigens [58]. They are essential in 
mucosal immune tolerance and during normal homeostasis of the gut. Tregs have the capacity to 
actively block immune responses as they have been implicated in the suppression of T cell activation, 
proliferation and cytokine production through mechanisms not fully known [59]. They play a key role 
in regulating immune responses as a global ―brake‖ on immunity [60]. Treg action is through the 
production of bioactive molecules, such as IL-10 and TGF- as well as through cell-cell contact [61]. 
A  lot  of  observations  suggest  flexibility  in  polarization  of  human  cells.  Memory  T  cells  are 
considered flexible with regard to cytokine production. Several modes of plasticity of T cell subsets 
have recently been described (for review see [62]). TFH (Follicular Helper T cells), Th3, Tr1 and Th9 
have been proposed as new potential Th cell lineages but their formal status of subsets seems uncertain 
as they could represent subsets of Th1, Th2, Th17 or Treg lineage. Very recently, Th22 clones derived 
from patients with psoriasis and secreted IL22, and not IL-17, have been described. They infiltrate the 
epidermis in individuals with inflammatory skin disorders [63,64]. 
3.2. HIV and CD4
+ T Cell Depletion  
T lymphocyte numbers in the human body are kept constant by homeostatic mechanisms. These 
mechanisms fail in HIV infection characterized by progressive immune deficiency. Loss of CD4
+ T 
cells and systemic immune activation are the hallmarks of HIV infection. 
HIV pathogenesis can be divided into two major phases: the acute infection phase associated with a 
dramatic loss of CD4
+ T cells residing in mucosal tissue, especially in GALT (gut-associated lymphoid 
tissue) [23,65] and a chronic phase characterized by an immune activation with a massive production 
of proinflammatory cytokines [66,67], which in turn is responsible for clonal deletion [32,68] and 
gradual loss of peripheral CD4
+ T cells over time [68,69]. 
During primary HIV-1 infection, the number of CD4
+ T cells declines in association with high 
viremia levels, before the onset of antiviral immune response. HIV-1 infects preferentially those CD4
+ Viruses 2011, 3                         
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T cells that are HIV-1 specific, rather than CD4
+ T cells specific for unrelated antigens [70]; moreover, 
ex vivo HIV-1 specific CD4
+T cells have greater apoptotic potential than those specific for CMV [71]. 
Loss of CD4
+ T cells after HIV infection is also a result of several mechanisms such as impairment 
of de novo production of T lymphocytes by the thymus, induction of syncytium formation, alteration 
of membrane permeability, mitochondrial dysfunction, killing by HIV-specific cytotoxic T cells or 
through expression of DRs due to heightened levels of immune activation. The importance of each will 
be discussed below. The thymus, the primary organ of thymopoiesis, is highly active during early life 
and thymic output and function progressively declines during ageing  [72]. HIV infection leads to 
major alterations in T cell homeostasis due in part to destruction of thymic structures [73], reducing 
input of naïve CD4
+ T cells into peripheral naïve T cell pool compared to uninfected individuals [74]. 
However, in almost all cases, loss of CD4
+ T cells is associated with apoptosis which represents the 
major mechanism of CD4
+ T cell depletion [75–77] and the number of apoptotic cells greatly exceeds 
the number of HIV-infected cells [77,78]. Apoptosis in lymph nodes is observed primarily in the HIV-
negative cell fraction [79] leading to the conclusion that during HIV-1 infection, apoptosis occurs in 
bystander cells and not only in the productively infected cells themselves.  
3.3. The Direct Cytopathic Effect of HIV-1 
After HIV-1 infection, lymphoid tissue has been identified as a major site of HIV replication and a 
reservoir for HIV in vivo [80,81]. CD4
+ T cells in the GI tract are 10-fold more frequently infected by 
the virus than are those in the peripheral blood [82], and the GI tract shows the most substantial CD4
+ 
T cell depletion at all stage of HIV disease, which affects the CCR5
+ CD4
+ T cell subset, the majority 
of GI tract CD4
+ T cells [22]. Infection frequencies of other mucosal lymphoid sites could be similar to 
those in blood (0.01–1% CD4
+ T cells) [83].  
The mechanisms of this cell death could have two explanations: a direct killing via virus-induced 
cytolysis by mechanisms related to direct infection of the cells [84] and the killing of virus-infected 
cells which  occurs  via the immune  surveillance through the action  of killer  T cells  [85,86]. HIV 
specific CD8
+ T cells play a key role in the control of viral replication. Appearance of CTL responses 
at early stage of infection coincides with a rapid fall in plasma viremia [87]. CTLs recognize short 
epitopes associated with class I molecules of the major histocompatibility complex (MHC). However, 
selection of escape mutants is a major driving force of HIV evolution [88]. This phenomenon leads to 
an  immediate  decline  of  the  corresponding  CTL  responses  [89].  These  responses  exert  a  strong 
selection pressure, but as the founder epitopes are replaced by mutational variants, these responses are 
always race against the clock with de novo development of responses to epitope variants. Beneficial 
effects of CTL responses are largely impaired and do not avoid viral load at a high level during 
chronic infection [86]. 
Syncytia are generated by the fusion of HIV-infected cells, expressing Env (gp120/gp41) on the 
plasma membrane, with uninfected target, expressing a suitable coreceptor (CD4 or CCR5); however, 
the vast majority of syncytium-inducing HIV-1 variants employ CXCR4 as a coreceptor [90]. Syncytia 
are condemned to die by apoptosis after a latency phase explained in part by genomic instability [91], 
but  p53  emerges  also  as  a  critical  mediator  of  syncytial  apoptosis  [92].  Syncytia  are  frequently 
observed in vitro [93]. In vivo, biopsy and autopsy studies revealed that HIV-infected multinucleated Viruses 2011, 3                         
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cells, presumably formed by cell-cell fusion, are present in brain and lymphoid tissue of HIV-infected 
patients thus contributing to the depletion of CD4
+ T cells. However, the overall extent of cell-cell 
fusion in vivo has not been estimated [93]. 
Whereas direct cytopathic effects affect the survival of infected CD4
+ T cells, indirect mechanisms, 
such as activation-induced cell death, are likely to play a major role in elimination of uninfected CD4
+ 
T cells, corresponding to ―bystander‖ cells. 
3.4. Hyperactive Immune State Upon HIV Infection 
During chronic untreated HIV infection, practically every arm of the immune system that has been 
investigated has been shown to be in a hyperactive state: high T cell turnover, nonspecific T cell 
activation and proliferation, polyclonal activation of B cells and elevated proinflammatory cytokines 
are characteristic of HIV infection [94]. HIV, through the induction of immune activation, generates its 
own targets for replication. 
A direct link between immune activation in chronic HIV infection and catastrophic events occurring 
at the mucosal surfaces during acute infection has been provided by recent studies. HIV causes a 
profound  and  complex  disturbance  of  the  mucosal  immune  function.  In  chronic  HIV  infection, 
intestinal permeability and enteropathy (diarrhea, gastrointestinal inflammation, malabsorption) are 
increased [95], a poorly controlled translocation of immunostimulatory microbial products occurs and 
correlates with immune activation markers, which in turn, are associated with disease progression [96]. 
Th17 cells are important for intestinal homeostasis [97]; they are involved in control of epithelial 
integrity of the gastrointestinal barrier and microbial invasion.  
In healthy donors, there is a significantly higher frequency of IL-17-producing CD4
+ T cells in the 
GI tract compared to peripheral blood (about 6% versus 2% respectively). During HIV infection, Th17 
cells appear to be preferentially lost from the gastrointestinal tract, relatively early in the disease [98], 
even  in  patients  with  a  high  absolute  CD4
+  T  cell  count.  In  blood  of  chronically  HIV-infected 
individuals, the proportion of Th17 cells is reduced 10-fold compared to HIV-uninfected controls [95]. 
Th17 cells represent ideal targets for HIV by virtue of high expression of the second receptor CCR5 
and low secretion of CCR5 ligands MIP-1 and MIP-1 [99]. They are permissive to HIV infection  
in vitro and in vivo, but they do not appear to be the preferential targets of HIV [98]. Nevertheless, 
there is a preferential depletion of Th17 in the gut of HIV-infected humans. CD161
+ CD4
+ T cells, 
identified as gut homing Th17 precursor population [100], express particularly high level of CCR5, are 
permissive to HIV infection and are also lost during HIV infection. Depletion of Th17 cells and their 
precursors is mediated by direct infection of target cells, bystander apoptosis or a combination of 
mechanisms like other infected CD4
+ T cells. Moreover, CD4
+ T cells in HIV-infected patients are 
skewed toward a Th1 phenotype to the detriment of Th17 cells. This combined loss of Th17 and their 
precursor CD161
+CD4
+ T cells may contribute to impaired mucosal T cell immunity and microbial 
translocation [95]. The disturbed GALT function, depletion of Th17 and microbial translocation are 
accompanied by an incessant vicious circle of immune activation and inflammation with deleterious 
consequences on viral replication, T cell and epithelial death, and dysfunction of multiple additional 
cells [101]. One major consequence for the immune system is an increasing of activation-induced T Viruses 2011, 3                         
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cell death (AICD) leading to an exacerbation of physiologic mechanisms which control peripheral T 
cell depletion following an immune response [102].  
A  very  recent  paper  revisits  the  mechanisms  by  which  CD4  T  cells,  in  lymphoid  tissues,  are 
depleted in HIV-infected hosts [103]. Authors suggested that the vast majority of bystander cell death 
in these tissues involved abortive HIV infection: naïve CD4
+ T cells are refractory to productive HIV 
infection; after viral entry, infection is aborted as reverse transcription is initiated but fails to reach 
completion [104,105]. Accumulation of incomplete reverse transcripts in nonpermissive resting CD4
+ 
T  cells  activates  a  host  defense  program  that  elicits  proapoptotic  and  proinflammatory  responses 
involving caspase-3 and caspase-1 activation. 
3.5. HIV and Activation-Induced T Cell Death 
During the termination phase of an immune response, the death of activated lymphocytes serves to 
limit the immune response by killing cells that are no longer needed. Molecular mechanisms involved 
in the death of peripheral T cells have been recently reviewed [12]. These mechanisms depend on the 
expression  of  TNF  superfamily  ligands  and  their  receptors,  e.g.,  Fas/FasL  and  TRAIL-DR5 
[106,107,108]  (Figure  1).  After  acute  and  during  chronic  HIV  infection,  immune  activation  is 
exacerbated and drives cells into apoptosis, reflecting an amplified normal process for homeostatic cell 
regulation. 
Naïve T cells (CD45RA
+) express little or no cell-surface FasL, while it is expressed in relatively 
large amounts by previously activated T cells (CD45RO
+). Expression of c-myc is required for the 
activation-induced expression of FasL [109], upon which mature T-cell AICD depends. AICD utilizes 
at least in part the Fas/FasL system; but significantly, functionally distinct subsets of CD4
+ T-helper 
cells have different sensitivities to AICD: after TCR ligation, Th1 cells express significantly higher 
levels of FasL and undergo AICD much more readily than do Th2 cells [110] (Figure 1). TRAIL 
contributes also to AICD in T cells but is exclusively observed in Th2 clones and primary T helper 
cells differentiated under the Th2 conditions [111,112]. Curiously, infected cells are more resistant to 
apoptosis than uninfected cells [113]; this involves a modulation of the mitochondrial pathway of 
apoptosis [114]. A consequence of this is that indirect cell killing via Fas/FasL will destroy activated 
but uninfected cells while sparing the fraction of infected cells. 
Low frequencies of APC (CD13
+ myelomonocytic cells, comprising macrophages, dendritic cells 
and granulocytes) were observed within the GI tracts of HIV-infected patients [98] and may contribute 
to an altered cytokine environment required for Th17 development and would favor the differentiation 
of CD4
+ T cells along a Th1 rather than a Th17 pathway [115]. Th1 are highly sensitive to AICD and 
are lost more rapidly than the other Th cells [110]. Thus if Th17 cells, expressing the HIV receptor 
CCR5, and their precursors CD161
+ T cells are lost mainly by cytopathic effect of the virus, and the 
cytokinic context in gut is modified by a change in proportion of antigen-presenting cells, favoring 
Th1 development instead of Th17, this could explain (in part) the preferential depletion of Th17 in the 
gut. As Th1 cells are very sensitive to AICD, in a context of hyperactive immune state, this could 
explain (also in part) the massive loss of CD4
+ T cells during HIV infection. Viruses 2011, 3                         
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3.6. Role of Regulatory T Cells in HIV Disease Progression 
Tregs represent a heterologous population with different localizations but with equal suppressive 
capacities  [54].  In  healthy  subjects,  Tregs  show  higher  turnover  rates  in  vivo  compared  to  
conventional CD4
+ T cells, without any immune activation [116,117]. The mechanisms of Treg cell 
function  are  still  a  matter  of  debate,  but  they  can  be  grouped  into  four  basic  ‗modes  of  action‘: 
suppression  by  inhibitory  cytokines  as  IL-10  and  TGF-  [118]  suppression  by  cytolysis  [119], 
suppression by metabolic disruption and suppression by modulation of dendritic cell (DC) maturation 
or function [120]. However, it seems that apoptosis induction in T effector cells is not important for 
human Treg mediated suppression [121]. 
Tregs, as conventional T cells, are progressively lost during HIV infection. Indeed, during HIV 
chronic infection, frequency of circulating Tregs is higher compared to normal controls, but their 
absolute counts are substantially decreased [122] and immune activation increases with decline in Treg 
count [95]. The fall in circulating Treg number may be explained by several mechanisms: preferential 
HIV infection and/or apoptotic properties of Tregs and/or relocalization in other lymphoid tissue.  
Tregs express HIV co-receptors CCR5 and CXCR4, and are susceptible to HIV infection [53] only 
if  they  are  previously  stimulated  [123].  Precursor  population  of  Treg  cells,  termed  naïve  Tregs 
(nTregs), isolated from peripheral blood has been phenotyped as CD4
+CD45RA
+CD25
+ and expressed 
high level of FoxP3 mRNA and protein. After TCR activation, these cells express high levels of HIV 
co-receptors  CCR5  and  CXCR4  and  are  preferentially  infected  by  HIV  early  after  activation, 
compared to naïve CD4
+ T cells [124].  
Little  information  is  available  regarding  the  homeostasis  of  Tregs  and  relevant  mechanisms  in 
chronic HIV infection. Treg cells display a rapid turnover level indicated by a proliferation marker 
(Ki-67) and apoptosis markers (active caspase-3 and Annexin-V) ex vivo in HIV-infected subjects. 
This  turnover  was  associated  with  disease  progression  and  is  positively  correlated  with  immune 
hyperactivation [125]. Freshly isolated human Tregs are highly sensitive to CD95-mediated apoptosis 
but show a relative resistance to AICD [126]. This susceptibility to apoptosis has also been attributed 
to  low  levels  of  the  antiapoptotic  molecule  bcl-2  [116].  On  the  contrary,  nTregs  showing  unique  
self-generating capacities seem to be more resistant to apoptosis [127].  
Chronic HIV infection changes CD4
+CD25
+ Treg tissue distribution [128] with an increase of these 
cells in peripheral lymph nodes and mucosal lymphoid tissues where most HIV replication occurs: 
when frequencies of Tregs are compared in peripheral blood and in duodenal mucosa, the frequency 
and the absolute count of mucosal Tregs are highly increased in untreated HIV patients [129–131].  
HIV binding on Tregs increases the expression of homing receptors CD62L and 47, enhances 
their homing to peripheral and mucosal lymph nodes, and enhances their survival [123] 
HIV induces abnormal development of Tregs in the thymus, resulting in an enrichment of Tregs 
[74]. The consequences are ambiguous: as Tregs suppress T cell activation, they could be of either 
benefit—diminishing  bystander  apoptosis,  T  cell  loss  and  hyperactivation—or  detrimental—
impairment of HIV-specific responses and participation to viral persistence. Study of natural hosts of 
SIV can yield important information regarding resistance to pathogenesis. After SIV infection, natural 
hosts (e.g., African green monkeys, sooty mangabeys) do not progress to clinical AIDS; they maintain 
high SIV viral loads, but avoid the chronic, generalized immune system activation associated with Viruses 2011, 3                         
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disease progression in HIV-infected individuals [132]. Both Th17 and Tregs are preserved. During 
HIV infection, frequency of Tregs is significantly increased in thymus, but input of these cells into 
peripheral T cell pool does not allow the preservation of this population as their absolute counts are 
substantially decreased [122]. The ability of this subset to elicit a beneficial effect is impaired. 
4. HIV Protein and Apoptosis 
Only 0.00001 to 0.01% of HIV-1 virions are infectious in vitro and in vivo. Thus, noninfectious 
virions may contribute to HIV-1 pathogenicity by inducing bystander T-cell apoptosis.  
In addition to infecting and killing of CD4
+ T cells, virtually every protein encoded by HIV can 
influence apoptosis in host cells [133] but the major players in HIV-induced apoptosis are Env, Nef, 
Tat,  HIV  protease  and  Vpr.  They  kill  infected  and  uninfected  lymphocytes  through  intrinsic  or 
extrinsic pathways (Figure 1).  
4.1. Env (gp 120) 
Envelope glycoproteins have been implicated as the major cause of bystander cell death in T and 
other cell types [134]. Sources of gp120 are multiple: soluble gp120 resulting from shedding of the 
surfaces  of  the  viral  particles  or  infected  cells,  Env  expressed  on  virions  or  at  the  surface  of  
infected cells.  
Cross-linking  of  the  cellular  receptor  (CD4)  and  co-receptor  CCR5  with  gp120  activates  the 
Fas/FasL (CD95/CD178) pathway and downmodulates a caspase inhibitor, the FLICE (FADD-like 
interleukin1-converting  enzyme)-like  inhibitory  protein  (FLIP)  [135].  This  extrinsic  pathway 
involves cell death receptors leading to the downregulation of bcl-2 and the activation of caspases 8 
and 10, which in turn activate caspase 3 to initiate apoptosis. Intrinsic mechanisms of Env-mediated 
apoptosis have been described: engagement of CD4, expressed on uninfected cells, separately from 
TCR, with Env expressed on the surface of infected cells influences the expression of the proapoptotic 
protein Bax, which in turn induces dissipation of the mitochondrial transmembrane potential m that 
could  initiate  apoptosis  in  lymphocytes  [5].  CXCR4,  a  natural  co-receptor  of  HIV  Env,  can  also 
transduce a death signal when bound to Env through mitochondrial transmembrane depolarization, 
cytochrome C release and activation of caspase-9 [136]. 
Env from both R5 and X4 strains triggers autophagy and cell death in bystander CD4
+ T cells [137]. 
It is a cell-type dependent process [138]. Currently, it is not known how autophagy is controlled, and 
what the importance of this phenomenon is in general CD4
+ T cell depletion during HIV infection. 
4.2. Nef 
Nef (negative factor) protein is one of the earliest and most abundantly expressed viral proteins 
preliminary localized to cellular membrane. It is also present in the serum of infected individuals 
[139]. HIV-1 Nef protein (27 kDa) consists of four regions and its cellular localization depends on its 
conformation  allowing  interactions  with  many  different  cellular  proteins.  Among  the  pleiotropic 
effects of this protein, Nef modulates surface expression of various cellular proteins including CD4 
and  MHC  class  I  and  II,  is  required  for  the  efficient  replication  of  the  virus  and  affects  signal Viruses 2011, 3                         
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transduction pathways. Endogenous Nef upregulates both Fas and FasL [140]. Soluble extracellular 
Nef induces apoptosis in bystander T cells indirectly via the increased expression of FasL on infected 
cells [141] or directly by interacting with the CXCR4 chemokine receptor [142]. Nef can also be 
released in the plasma from HIV-infected individuals, in exosome-like microvesicles containing CD45 
(leukocyte common antigen). As long as they contain Nef, these vesicles cause activation-induced cell 
death of resting CD4
+ T cells [143,144]. The predominant mechanism of Nef-induced apoptosis is 
associated with death receptors; however, Nef may also trigger the intrinsic pathway by decreasing 
bcl-2  and  bcl-XL  expression  and  increasing  caspase-mediated  effects  [145].  Depending  on  the 
situation, Nef can be anti-apoptotic [5,144]. 
4.3. Tat 
Tat (Trans Activating Factor) is a regulatory protein of HIV indispensable for viral replication. Tat 
can  be  secreted  in  plasma  from  HIV-infected  patients  and  can  cross  the  cell  membrane  to  enter 
uninfected  cells  [146,147].  This  protein  triggers  extrinsic  and  intrinsic  apoptosis  pathways  in  
both  infected  and  uninfected  cells  [148].  For  the  first  pathway,  Tat  induces  the  upregulation  of  
Fas/FasL-mediated apoptosis, and when secreted it enhances the susceptibility of bystander cells to 
Fas-mediated killing [149,150]. Activated FOXO3a (Forkhead box transcription factor O class 3a) 
controls the expression of several proapoptotic genes, including FasL, Bim and TRAIL. Tat protein 
can activate the Egr1-PTEN-FOXO3a pathway leading to apoptosis of HIV-infected and non-infected 
cells [151]. Association of Tat with PTEN and PP2A promoters has been identified as the initiating 
event of Tat-mediated apoptosis [152]. Tat protein is implicated in the intrinsic apoptosis pathway 
through interactions with numerous intracellular targets. Tat stimulates the transcription of cyclin B1, 
which increases cyclin B1 level and promotes cell apoptosis  [153]. Tat decreases bcl-2 [154] and 
increases Bax, caspase 8 expression [155]. Several mitochondrial interactions of this protein have been 
described: disruption of mitochondrial calcium homeostasis, down regulation of mitochondrial isoform 
of  superoxide  dismutase,  translocation  of  Bim  (Bcl-2  interacting  mediator  of  cell  death)  from 
microtubules to mitochondria [5]. 
4.4. HIV Protease 
The essential role of HIV protease is the cleavage of viral precursor proteins to yield mature virion 
proteins.  In  addition  to  its  role  in  viral  replication,  HIV  protease  may  also  contribute  to  HIV 
pathogenesis.  The  protease  substrate  specificity  is  not  restricted  to  viral  proteins  since  the 
cytoprotective protein bcl-2 could be cleaved by HIV protease, leading to apoptosis [156]. Moreover, 
this viral enzyme directly cleaves procaspase 8 generating a novel peptide, casp8p41, and thus triggers 
the mitochondrial-dependent pathway of apoptosis that involves cleavage of Bid, loss of mitochondrial 
potential  and  nuclear  fragmentation.  After  in  vitro  HIV-infection,  almost  all  casp8p41
+  cells  are 
apoptotic whereas casp8p41
− cells are not. In cells from HIV-1 patients, this peptide is present only in 
CD4
+ T cells, predominantly the memory subset, and initiates apoptotic cell death. Exogenous protease 
does not kill uninfected cells [157]. This mechanism may contribute to death of HIV-1 infected cells. Viruses 2011, 3                         
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4.5. Vpr 
Vpr (Virus protein R) is a virion-associated accessory protein necessary for virus replication [158]. 
It is expressed at the late stage of the virus life cycle, but is present during the early steps of infection 
because it is packaged into viral particles. HIV-1 Vpr exists in three forms: soluble, intracellular and 
virion-associated. Vpr, incorporated into the HIV-1 virion, shows multiple activities including nuclear 
transport of the preintegration complex to the nucleus, activation of the transcription, cell cycle arrest 
at the G2/M transition (cells infected with HIV-1 cease to proliferate) and induction of apoptosis. The 
cell  cycle  transition  into  G2  is  required  for  Vpr  to  induce  apoptosis.  Muthumani  et  al.  [159] 
demonstrated  that  Vpr  induces  apoptosis  via  the  intrinsic  pathway.  Virion  associated  Vpr  caused 
activation of initiator caspases 8 and 9 and effector caspases 3/7 and a drop of m confirming that 
death  is  initiated.  Furthermore,  the  mitochondrial  protein  Bax  (an  independent  mitochondrial  
pore-forming protein), has been identified as the key executioner of apoptosis in the context of HIV-1 
vpr  [160].  It  is  confirmed  in  human  activated  PBMCs  [161].  It  has  been  recently  proposed  that  
virion-associated  Vpr  could  amplify  Fas-induced  cell  death,  a  process  that  could  involve  the 
amplification effect of caspase 8 through the mitochondrial pathway [161]. So, Vpr can contribute to 
the depletion of CD4
+ T lymphocytes either directly or by enhancing Fas-mediated apoptosis during 
acute HIV-1 infection.  
5. Conclusion 
HIV infection is associated with a progressive decline of circulating CD4
+ T cells and loss of 
immune  functions;  however  this  infection shows a  more  severe depletion  of CD4
+ T cells in  the  
gastro-intestinal tract than in blood [22,23,162]. In the acute phase of infection, the virus depletes 
CD4
+  T  cells  in  the  mucosal  tissue  of  the  gut  as  they  represent  the  ―ideal  targets‖  of  the  virus 
(activated CD4
+ T cells, near the front door of the virus, at the lining of the vagina or anus). In this 
process,  the  virus  also  destroys  the  gut  mucosas‘s  structural  cells,  allowing  gut  bacteria  or  other 
pathogens to penetrate the body; these phenomena lead to irreversible damage to the immune system. 
Finally,  HIV  triggers  chronic  immune  activation.  Recently,  a  strong  association  between  the 
destruction of intestinal CD4
+ T cell homeostasis in the gut and the level of systemic CD4+ T cell 
activation [162] has been described. 
The relationship between hyperimmune activation and loss of CD4
+ T cells has been analyzed in 
different systems. First, natural hosts of SIV (HIV-like simian immunodeficiency virus), monkeys 
from Africa, do not show immune activation, do not lose their CD4
+ T cells and do not evolve to AIDS 
whereas asian monkeys, nonnatural hosts, develop the pathology after SIV infection. It is fundamental 
to elucidate the mechanisms that allow natural hosts to coexist with SIV without overt disease [132]. 
Second, the initiation of antiretroviral therapy (ART) has significantly reduced morbidity and mortality 
of HIV-infected patients. This therapy has the ability to restore a normal circulating CD4
+ cell count in 
most patients, associated with a low to undetectable plasma HIV RNA level [163]; however, there 
exists significant patient-to-patient heterogeneity as there is no consensus with regard to how to best 
define immunological success or failure of the treatment. From studies of large cohorts, up to 10 to 
30% of patients fail to achieve CD4
+ T cell counts of > 500 cells/μL and high levels of gut-associated Viruses 2011, 3                         
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HIV-DNA  are  associated  with  persistent  immune  activation  and  microbial  translocation  [164].  It  
has  been  hypothesized  that  this  might  be  related  to  persistent  dysregulation  of  gut  CD4
+  Th17  
subsets [165]. 
Finally, the study of the immunological responses of resistant patients to the disease progression 
(LTNP  and  elite  suppressors  representing  10–15%  and  less  than  1%  of  HIV-infected  population, 
respectively) would give us important information concerning factors involved in disease progression 
and  responses  to  be  induced  upon  vaccination.  Indeed,  these  populations  are  actively  studied  to 
understand how infected individuals control viral replication and immune activation for at least 10 
years. Is it virus, or is it the host or is it all in the genes [166–171]? A very recent paper shows that 
LTNPs have intact CD4
+ T cell populations in the gut mucosa with similar IL-17 expression and 
plasma LPS level to HIV-uninfected controls [172].  
The next question is how can therapeutic strategies reproduce this privileged status without adapted 
genetic background? One thing appearing fundamental is the necessity to preserve the integrity of the 
gut mucosa; one approach would be to ‖test and treat‖, a prevention strategy that promotes HIV testing 
and initiating antiretroviral therapy upon diagnosis, regardless of CD4 cell count [173]. According to 
the  published  results,  the  most  important  step  to  control  HIV  infection  should  be  to  manage  the 
integrity of the gut mucosa. 
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